Predict your next investment

Corporate Venture

See what CB Insights has to offer

Investments

18

Portfolio Exits

2

About Zhongwei Fund

Zhongwei Fund is a venture arm under Tianyi Group.

Zhongwei Fund Headquarter Location

Shanghai, Shanghai,

China

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Zhongwei Fund News

China: Zhongwei backs Vedeng; SDIC invests in Innovent Biologics

Nov 30, 2016

China: Zhongwei backs Vedeng; SDIC invests in Innovent Biologics Subscribe to our newsletter Tomas S. Noda III November 30, 2016: &nbsp Two healthtech startups in China, Vedeng Corp , and Innovent Biologics , have raised $9.4 million, and $260 million respectively in separate funding rounds, the China Money Network reported. Zhongwei backs Vedeng $9.4m in Series A Vedeng Corp, a medical equipment B2B e-commerce portal in China, raised $9.4 million in its Series A round funded by investment platform Zhongwei Fund . Zhongwei Fund is owned by the former parent company of Meinian Onehealth Healthcare Holdings Co Ltd, Oriental Fortune Capital and Puhua Capital. The latter is a local venture capital firm focused on healthcare, and has backed surgical robot firm Remebot and iGeneTech, a genetic testing design platform in China. Zhongwei Fund is one of many healthcare-focused investment funds under Shanghai Tianyi Group, from which Meinian Onehealth was seeded. Vedeng previously raised RMB30 million in a pre-A round from Share Capital and a Shenzhen investment fund in 2015. It claims to have over 50,000 dealers on its platform, which covers all major clinics and hospitals in China. And with a team of nearly 20,000 medical equipment engineers on call, Vedeng also helps provide after-sales services on behalf of manufacturers. The Nanjing-based Vedeng launched its platform in 2012, connecting upstream manufacturers with medical equipment dealers and private clinics. Also Read: Chinese biopharma firm CStone gets $150m Series A from Oriza, Boyu, WuXi SDIC leads $260m Series D in Innovent Biologics Biopharmaceutical firm Innovent Biologics has reportedly received $260 million in a Series D round led by vehicle fund managed by Chinese state-owned investment entity State Development & Investment Corp (SDIC) . Other companies that joined the round were new investors China Life Investment Holding Co Ltd, Taikang Insurance Co Ltd, Ping An Insurance, and also existing investors Legend Capital, Temasek Holdings, and Hillhouse Capital. Innovent Biologics will realise a total funding of $410 million once the latest round is completed. Its goal is to bring highly complex drugs to the masses. Innovent Biologics plans to use the proceeds of the latest funding on research and development of new drugs, and expand its industrialisation capabilities. Founded in 2011, Innovent Biologics’s product portfolio includes 12 anti-body covering oncology, immunity and cardiovascular diseases, of which four have entered the clinical stage. In 2015, Innovent Biologics entered into an agreement with Eli Lilly to co-develop and co-commercialize six antibody drugs over the next 10 years. It became the first biopharmaceutical product invented by a Chinese firm to be licensed to a global company. Also Read:

Zhongwei Fund Investments

18 Investments

Zhongwei Fund has made 18 investments. Their latest investment was in Shenbo Medical as part of their Seed VC on May 5, 2019.

CBI Logo

Zhongwei Fund Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

5/24/2019

Seed VC

Shenbo Medical

Yes

1

8/24/2018

Series A

Genepoint Biological Technology

Yes

4

4/24/2018

Series A

Zhangzhongyi

$15.45M

Yes

5

2/22/2018

Series A

Subscribe to see more

$99M

Subscribe to see more

10

2/8/2018

Series C

Subscribe to see more

$99M

Subscribe to see more

10

Date

5/24/2019

8/24/2018

4/24/2018

2/22/2018

2/8/2018

Round

Seed VC

Series A

Series A

Series A

Series C

Company

Shenbo Medical

Genepoint Biological Technology

Zhangzhongyi

Subscribe to see more

Subscribe to see more

Amount

$15.45M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

4

5

10

10

Zhongwei Fund Portfolio Exits

2 Portfolio Exits

Zhongwei Fund has 2 portfolio exits. Their latest portfolio exit was CareRay on February 01, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

2/1/2021

IPO

$991

2

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

Date

2/1/2021

00/00/0000

Exit

IPO

Subscribe to see more

Companies

Subscribe to see more

Valuation

$991

$991

Acquirer

Subscribe to see more

Sources

2

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.